Subsidiary of FOSUN PHARMA Gains Approval for Pertuzumab Injection

Stock News05-29

FOSUN PHARMA (600196.SH) announced that its controlling subsidiary, Shanghai Henlius Biotech, Inc., and its controlled subsidiaries (collectively referred to as "Henlius") have received approval from the National Medical Products Administration for the market registration application of their self-developed pertuzumab injection (domestic brand name: Han Bei You®). The approved indications cover all indications for which the original pertuzumab injection has been approved in China, specifically including: 1. Early Breast Cancer: In combination with trastuzumab and chemotherapy for: (1) Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early breast cancer (tumor diameter >2cm or lymph node-positive), as part of a complete early breast cancer treatment regimen; (2) Adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. 2. Metastatic Breast Cancer: In combination with trastuzumab and docetaxel, for the treatment of patients with HER2-positive metastatic or unresectable locally recurrent breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109704816?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109704816","market":"other","top_or_hot":-1,"title":"Subsidiary of FOSUN PHARMA Gains Approval for Pertuzumab Injection","media":"Stock News","content":"<p>FOSUN PHARMA (600196.SH) announced that its controlling subsidiary, Shanghai Henlius Biotech, Inc., and its controlled subsidiaries (collectively referred to as \"Henlius\") have received approval from the National Medical Products Administration for the market registration application of their self-developed pertuzumab injection (domestic brand name: Han Bei You®). The approved indications cover all indications for which the original pertuzumab injection has been approved in China, specifically including: 1. Early Breast Cancer: In combination with trastuzumab and chemotherapy for: (1) Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early breast cancer (tumor diameter >2cm or lymph node-positive), as part of a complete early breast cancer treatment regimen; (2) Adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. 2. Metastatic Breast Cancer: In combination with trastuzumab and docetaxel, for the treatment of patients with HER2-positive metastatic or unresectable locally recurrent breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Subsidiary of FOSUN PHARMA Gains Approval for Pertuzumab Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSubsidiary of FOSUN PHARMA Gains Approval for Pertuzumab Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-29 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (600196.SH) announced that its controlling subsidiary, Shanghai Henlius Biotech, Inc., and its controlled subsidiaries (collectively referred to as \"Henlius\") have received approval from the National Medical Products Administration for the market registration application of their self-developed pertuzumab injection (domestic brand name: Han Bei You®). The approved indications cover all indications for which the original pertuzumab injection has been approved in China, specifically including: 1. Early Breast Cancer: In combination with trastuzumab and chemotherapy for: (1) Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early breast cancer (tumor diameter >2cm or lymph node-positive), as part of a complete early breast cancer treatment regimen; (2) Adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. 2. Metastatic Breast Cancer: In combination with trastuzumab and docetaxel, for the treatment of patients with HER2-positive metastatic or unresectable locally recurrent breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"","article_id":"1109704816","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109704816","pubTimestamp":1780044278,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (600196.SH) announced that its controlling subsidiary, Shanghai Henlius Biotech, Inc., and its controlled subsidiaries (collectively referred to as \"Henlius\") have received approval from...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0196":"行业龙头","BK0060":"抗癌","BK0187":"一线龙头","02196":"复星医药","BK0028":"国家队","BK0239":"医药制造","BK0175":"白马股","BK0183":"MSCI概念","BK0096":"民营医院","BK1191":"制药","BK1593":"医美概念股","BK0188":"融资融券","BK1515":"抗疫概念","BK0012":"证金概念"},"translate_title":"复星医药子公司帕妥珠单抗注射液获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (600196.SH) announced that its controlling subsidiary, Shanghai Henlius Biotech, Inc., and its controlled subsidiaries (collectively referred to as \"Henlius\") have received approval from the National Medical Products Administration for the market registration application of their self-developed pertuzumab injection (domestic brand name: Han Bei You®). The approved indications cover all indications for which the original pertuzumab injection has been approved in China, specifically including: 1. Early Breast Cancer: In combination with trastuzumab and chemotherapy for: (1) Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early breast cancer (tumor diameter >2cm or lymph node-positive), as part of a complete early breast cancer treatment regimen; (2) Adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. 2. Metastatic Breast Cancer: In combination with trastuzumab and docetaxel, for the treatment of patients with HER2-positive metastatic or unresectable locally recurrent breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109704816","isCrawlerRequest":true}